Navigation Links
VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results
Date:9/8/2009

MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, plans to announce the results from the EQUIP and CONQUER Qnexa(TM) phase 3 obesity clinical trials on September 9th prior to market open. The announcement will be followed by a webcast and conference call at 8:00 a.m. Eastern time.

Conference Call Information

Domestic callers: 1-800-967-7185

International callers: 1-719-325-2352

Webcast information: http://ir.vivus.com. A webcast replay will be available on the VIVUS web site for 30 days.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa(TM), has recently completed phase 3 clinical trials for the treatment of obesity. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

    CONTACT:

    VIVUS, Inc.                Investor Relations: The Trout Group
    Timothy E. Morris                              Brian Korb
    Chief Financial Officer                        646-378-2923
    650-934-5200
                               Media Relations:    Pure Communications, Inc.
                                                   Sheryl Seapy
                                                   949-608-0841

'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. VIVUS Reports Second Quarter 2009 Financial Results
2. VIVUS Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
3. WellPoint Announces Appearance at Upcoming Conference
4. Johnson & Johnson to Participate in Morgan Stanley Global Healthcare Unplugged Conference
5. NeoStem to Present at Rodman & Renshaws 11th Annual Healthcare Conference
6. BioCryst Executives to Present at Two Investor Conferences
7. SYGNIS to Present at the 11th Rodman & Renshaw Annual Global Investment Conference
8. NHP to Present at the BMO Capital Markets 2009 North American Real Estate Conference
9. Amgen to Present at the Baird Healthcare Conference
10. Gentiva(R) Health Services to Present at the Robert W. Baird & Co. Health Care Conference
11. Newly Formed American Society for Nanomedicine (ASNM) to Hold First Conference (www.amsocnanomed.org)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 2017 , ... Support of value-based care models requires collaboration across all facets ... industry solutions, Fogo Data Centers announces the launch of the Fogo Partner Community™. , ... one in which all systems work well, work together, and work together well. ...
(Date:2/21/2017)... (PRWEB) , ... February 21, ... ... of technology-enabled clinical trial solutions, today announced the further expansion of its ... applications they can leverage as part of Bioclinica’s extensive and growing eHealth ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based Jvion, ... analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, received ... giants including Accenture, GE Ventures, and Software AG , will bring top ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... chronically untreated despite the medical, mental health, and financial consequences of inaction. On ... to take action if they have concerns about their hearing. , Effective treatment ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... protein espresso drinks, announced its products are now available for purchase on RonnieColemanNutrition.com, ... Drink Mix has become popular among health-conscious consumers who love coffee but are ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 21, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Liver Cirrhosis Drugs Price Analysis and Strategies ... Cirrhosis market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Liver Cirrhosis ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/21/2017)... Research and Markets has announced the addition of ... to their offering. ... latest research Anthrax Drugs Price Analysis and Strategies - 2016, provides drug ... research answers the following questions: What are the ... positioned in the Global Anthrax market? What are the ...
Breaking Medicine Technology: